Paricalcitol

Paricalcitol

SCHEMBL3655

C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

VDR

The experimentally established mechanism targets of Paricalcitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
VDR known ✓ P11473 13/20 0.68
HDAC6 Q9UBN7 4/20 0.60
HDAC3 O15379 3/20 0.60
HDAC2 Q92769 2/20 0.60
NR1I2 O75469 2/20 0.57
PGR P06401 2/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
HTR1A P08908 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
SLC6A2 P23975 1/20 0.56
SLC6A4 P31645 1/20 0.56
ADRA1A P35348 1/20 0.56
PTGS2 P35354 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Paricalcitol SCHEMBL12553223 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2
Paricalcitol SCHEMBL12915640 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2
Paricalcitol SCHEMBL12464969 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2
Paricalcitol SCHEMBL12464945 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2
Paricalcitol SCHEMBL25447329 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2
Paricalcitol SCHEMBL21836180 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2
Paricalcitol SCHEMBL24066861 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2
Paricalcitol SCHEMBL6750666 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2
Paricalcitol SCHEMBL13575779 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2
Paricalcitol SCHEMBL12397908 1.00 VDR (0.68) VDRHDAC6HDAC3HDAC2NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5306 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2025-12-18 US claimed
US-20250339399-A1 SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) 2025-11-06 US claimed
US-20250242092-A1 SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS SIO2 MEDICAL PRODUCTS INC (US) 2025-07-31 US claimed
WO-2025133218-A1 PYRAZINE DERIVATIVES FOR THE TREATMENT OF SKIN DISORDERS PHAMRI NORDEN AB (SE) 2025-06-26 WO claimed
WO-2025129271-A1 LIPID DELIVERY VEHICLE THE UNIVERSITY OF QUEENSLAND (AU) 2025-06-26 WO claimed
WO-2025122686-A1 COMPOSITIONS AND METHODS FOR TREATING OBESITY YALE UNIVERSITY (US) 2025-06-12 WO claimed
WO-2025122021-A1 COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) 2025-06-12 WO claimed
WO-2025108575-A1 METHODS OF SELECTIVE DEPROTECTION AND SYNTHESIS OF TRANSHYDRINDANE- SKELETON-BASED COMPOUNDS ROCHE DIAGNOSTICS GMBH (DE) 2025-05-30 WO claimed
WO-2025111447-A1 TREATMENT OF CANCER WITH DRUG COMBINATIONS FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) 2025-05-30 WO claimed
EP-1178808-A1 PHARMACEUTICAL COMPOSITION LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 2002-02-13 EP claimed
US-20020012680-A1 Compositions and methods for improved delivery of lipid regulating agents LIPOCINE INC. 2002-01-31 US claimed
WO-2000072827-A9 POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF ACUSPHERE INC (US) 2002-01-31 WO claimed
EP-1158959-A1 COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS Lipocine, Inc. (US) 2001-12-05 EP claimed
US-6294192-B1 PHARMACEUTICAL COMPOSITIONS CAPABLE OF SOLUBILIZING THERAPEUTICALLY EFFECTIVE AMOUNTS OF HYDROPHOBIC THERAPEUTIC AGENTS. CARRIER INCLUDES A HYDROPHILIC SURFACTANT AND A HYDROPHOBIC SURFACTANT, AQUEOUS DISPERSION LIPOCINE, INC. 2001-09-25 US claimed
WO-2001037808-A1 SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS LIPOCINE, INC. (US) 2001-05-31 WO claimed
WO-2001028555-A1 EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS LIPOCINE, INC. (US) 2001-04-26 WO claimed
WO-2000072827-A2 POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF ACUSPHERE, INC. (US) 2000-12-07 WO claimed
WO-2000064450-A1 PHARMACEUTICAL COMPOSITION Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) 2000-11-02 WO claimed
WO-2000050007-A1 COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS LIPOCINE, INC. (US) 2000-08-31 WO claimed